Cite
APA Citation
de Bono, J. S., Mehra, N., Scagliotti, G. V., Castro, E., Dorff, T., Stirling, A., Stenzl, A., Fleming, M. T., Higano, C. S., Saad, F., Buttigliero, C., van Oort, I. M., Laird, A. D., Mata, M., Chen, H., Healy, C. G., Czibere, A., & Fizazi, K. (2021). talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. Lancet oncology, 22(9), 1250–1264. http://access.bl.uk/ark:/81055/vdc_100144484216.0x000031